157 related articles for article (PubMed ID: 9886377)
1. IL-12 is an effective adjuvant for induction of mucosal immunity.
Boyaka PN; Marinaro M; Jackson RJ; Menon S; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):122-8. PubMed ID: 9886377
[TBL] [Abstract][Full Text] [Related]
2. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
Marinaro M; Boyaka PN; Jackson RJ; Finkelman FD; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):114-21. PubMed ID: 9886376
[TBL] [Abstract][Full Text] [Related]
3. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.
Marinaro M; Staats HF; Hiroi T; Jackson RJ; Coste M; Boyaka PN; Okahashi N; Yamamoto M; Kiyono H; Bluethmann H; Fujihashi K; McGhee JR
J Immunol; 1995 Nov; 155(10):4621-9. PubMed ID: 7594461
[TBL] [Abstract][Full Text] [Related]
4. Mucosal immunity: regulation by helper T cells and a novel method for detection.
Jackson RJ; Marinaro M; VanCott JL; Yamamoto M; Okahashi N; Fujihashi K; Kiyono H; Chatfield SN; McGhee JR
J Biotechnol; 1996 Jan; 44(1-3):209-16. PubMed ID: 8717406
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
Strindelius L; Filler M; Sjöholm I
Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
[TBL] [Abstract][Full Text] [Related]
6. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella.
VanCott JL; Staats HF; Pascual DW; Roberts M; Chatfield SN; Yamamoto M; Coste M; Carter PB; Kiyono H; McGhee JR
J Immunol; 1996 Feb; 156(4):1504-14. PubMed ID: 8568254
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 12 and innate molecules for enhanced mucosal immunity.
Boyaka PN; Lillard JW; McGhee J
Immunol Res; 1999; 20(3):207-17. PubMed ID: 10741861
[TBL] [Abstract][Full Text] [Related]
8. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
Ohmura-Hoshino M; Yamamoto M; Yuki Y; Takeda Y; Kiyono H
Vaccine; 2004 Sep; 22(27-28):3751-61. PubMed ID: 15315856
[TBL] [Abstract][Full Text] [Related]
9. Lymphotactin acts as an innate mucosal adjuvant.
Lillard JW; Boyaka PN; Hedrick JA; Zlotnik A; McGhee JR
J Immunol; 1999 Feb; 162(4):1959-65. PubMed ID: 9973465
[TBL] [Abstract][Full Text] [Related]
10. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
[TBL] [Abstract][Full Text] [Related]
11. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
[TBL] [Abstract][Full Text] [Related]
12. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
Yamamoto M; Briles DE; Yamamoto S; Ohmura M; Kiyono H; McGhee JR
J Immunol; 1998 Oct; 161(8):4115-21. PubMed ID: 9780183
[TBL] [Abstract][Full Text] [Related]
13. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity.
Boyaka PN; Marinaro M; Jackson RJ; van Ginkel FW; Cormet-Boyaka E; Kirk KL; Kensil CR; McGhee JR
J Immunol; 2001 Feb; 166(4):2283-90. PubMed ID: 11160283
[TBL] [Abstract][Full Text] [Related]
14. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues.
Imaoka K; Miller CJ; Kubota M; McChesney MB; Lohman B; Yamamoto M; Fujihashi K; Someya K; Honda M; McGhee JR; Kiyono H
J Immunol; 1998 Dec; 161(11):5952-8. PubMed ID: 9834076
[TBL] [Abstract][Full Text] [Related]
15. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens.
Staats HF; Ennis FA
J Immunol; 1999 May; 162(10):6141-7. PubMed ID: 10229857
[TBL] [Abstract][Full Text] [Related]
16. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses.
Marinaro M; Boyaka PN; Finkelman FD; Kiyono H; Jackson RJ; Jirillo E; McGhee JR
J Exp Med; 1997 Feb; 185(3):415-27. PubMed ID: 9053442
[TBL] [Abstract][Full Text] [Related]
17. Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation.
Ohmura M; Yamamoto M; Tomiyama-Miyaji C; Yuki Y; Takeda Y; Kiyono H
Infect Immun; 2005 Jul; 73(7):4088-97. PubMed ID: 15972497
[TBL] [Abstract][Full Text] [Related]
18. RANTES potentiates antigen-specific mucosal immune responses.
Lillard JW; Boyaka PN; Taub DD; McGhee JR
J Immunol; 2001 Jan; 166(1):162-9. PubMed ID: 11123289
[TBL] [Abstract][Full Text] [Related]
19. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
[TBL] [Abstract][Full Text] [Related]
20. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
Arulanandam BP; O'Toole M; Metzger DW
J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
